Recent research have centered on the overlap of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and DA signaling. While GCGR agonists are increasingly employed for addressing type 2 diabetes mellitus, their unexpected consequences on reinforcement circuits, specifically influenced by DA net